Stem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will be used to help develop new heart failure drugs.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
